Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin after spinal surgery
IRCT20211109053014N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Occurrence of venous thromboembolism. Started Dec 2021; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20211109053014N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211109053014N1.